{"pmid":32357808,"title":"Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients.","text":["Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients.","The emerging COVID-19 caused by SARS-CoV-2 infection poses severe challenges to global public health. Serum antibody testing is becoming one of the critical methods for the diagnosis of COVID-19 patients. We investigated IgM and IgG responses against SARS-CoV-2 nucleocapsid (N) and spike (S) protein after symptom onset in the intensive care unit (ICU) and non-ICU patients. 130 blood samples from 38 COVID-19 patients were collected. The levels of IgM and IgG specific to N and S protein were detected by ELISA. A series of blood samples were collected along the disease course from the same patient, including 11 ICU patients and 27 non-ICU patients for longitudinal analysis. N and S specific IgM and IgG (N-IgM, N-IgG, S-IgM, S-IgG) in non-ICU patients increased after symptom onset. N-IgM and S-IgM in some non-ICU patients reached a peak in the second week, while N-IgG and S-IgG continued to increase in the third week. The combined detection of N and S specific IgM and IgG could identify up to 75% of SARS-CoV-2 infected patients in the first week. S-IgG was significantly higher in non-ICU patients than in ICU patients in the third week. In contrast, N-IgG was significantly higher in ICU patients than in non-ICU patients. The increase of S-IgG positively correlated with the decrease of C-reactive protein (CRP) in non-ICU patients. N and S specific IgM and IgG increased gradually after symptom onset and can be used for detection of SARS-CoV-2 infection. Analysis of the dynamics of S-IgG may help to predict prognosis.","Emerg Microbes Infect","Sun, Baoqing","Feng, Ying","Mo, Xiaoneng","Zheng, Peiyan","Wang, Qian","Li, Pingchao","Peng, Ping","Liu, Xiaoqing","Chen, Zhilong","Huang, Huimin","Zhang, Fan","Luo, Wenting","Niu, Xuefeng","Hu, Peiyu","Wang, Longyu","Peng, Hui","Huang, Zhifeng","Feng, Liqiang","Li, Feng","Zhang, Fuchun","Li, Fang","Zhong, Nanshan","Chen, Ling","32357808"],"abstract":["The emerging COVID-19 caused by SARS-CoV-2 infection poses severe challenges to global public health. Serum antibody testing is becoming one of the critical methods for the diagnosis of COVID-19 patients. We investigated IgM and IgG responses against SARS-CoV-2 nucleocapsid (N) and spike (S) protein after symptom onset in the intensive care unit (ICU) and non-ICU patients. 130 blood samples from 38 COVID-19 patients were collected. The levels of IgM and IgG specific to N and S protein were detected by ELISA. A series of blood samples were collected along the disease course from the same patient, including 11 ICU patients and 27 non-ICU patients for longitudinal analysis. N and S specific IgM and IgG (N-IgM, N-IgG, S-IgM, S-IgG) in non-ICU patients increased after symptom onset. N-IgM and S-IgM in some non-ICU patients reached a peak in the second week, while N-IgG and S-IgG continued to increase in the third week. The combined detection of N and S specific IgM and IgG could identify up to 75% of SARS-CoV-2 infected patients in the first week. S-IgG was significantly higher in non-ICU patients than in ICU patients in the third week. In contrast, N-IgG was significantly higher in ICU patients than in non-ICU patients. The increase of S-IgG positively correlated with the decrease of C-reactive protein (CRP) in non-ICU patients. N and S specific IgM and IgG increased gradually after symptom onset and can be used for detection of SARS-CoV-2 infection. Analysis of the dynamics of S-IgG may help to predict prognosis."],"journal":"Emerg Microbes Infect","authors":["Sun, Baoqing","Feng, Ying","Mo, Xiaoneng","Zheng, Peiyan","Wang, Qian","Li, Pingchao","Peng, Ping","Liu, Xiaoqing","Chen, Zhilong","Huang, Huimin","Zhang, Fan","Luo, Wenting","Niu, Xuefeng","Hu, Peiyu","Wang, Longyu","Peng, Hui","Huang, Zhifeng","Feng, Liqiang","Li, Feng","Zhang, Fuchun","Li, Fang","Zhong, Nanshan","Chen, Ling"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32357808","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1080/22221751.2020.1762515","keywords":["covid-19","igg","igm","sars-cov-2"],"locations":["S-IgM"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138495321636864,"score":9.490897,"similar":[{"pmid":32330303,"title":"Characteristics of Patients with Coronavirus Disease (COVID-19) Confirmed using an IgM-IgG Antibody Test.","text":["Characteristics of Patients with Coronavirus Disease (COVID-19) Confirmed using an IgM-IgG Antibody Test.","Coronavirus disease (COVID-19), caused by a novel betacoronavirus, SARS-CoV-2, has rapidly developed into a pandemic since it was first reported in December 2019. Nucleic acid testing is the standard method for the diagnosis of viral infections. However, this method reportedly has a low positivity rate. To increase the sensitivity of COVID-19 diagnoses, we developed an IgM-IgG combined assay and tested it in patients with suspected SARS-CoV-2 infection. In total, 56 patients were enrolled in this study and SARS-CoV-2 was detected by using both IgM-IgG antibody and nucleic acid tests. Clinical and laboratory data were collected and analyzed. Our findings suggest that patients who develop severe illness might experience longer virus exposure times and develop a more severe inflammatory response. The IgM-IgG test is an accurate and sensitive diagnostic method. A combination of nucleic acid and IgM-IgG testing is a more sensitive and accurate approach for diagnosis and early treatment of COVID-19. This article is protected by copyright. All rights reserved.","J Med Virol","Xie, Jiajia","Ding, Chengchao","Li, Jing","Wang, Yulan","Guo, Hui","Lu, Zhaohui","Wang, Jinquan","Zheng, Changcheng","Jin, Tengchuan","Gao, Yong","He, Hongliang","32330303"],"abstract":["Coronavirus disease (COVID-19), caused by a novel betacoronavirus, SARS-CoV-2, has rapidly developed into a pandemic since it was first reported in December 2019. Nucleic acid testing is the standard method for the diagnosis of viral infections. However, this method reportedly has a low positivity rate. To increase the sensitivity of COVID-19 diagnoses, we developed an IgM-IgG combined assay and tested it in patients with suspected SARS-CoV-2 infection. In total, 56 patients were enrolled in this study and SARS-CoV-2 was detected by using both IgM-IgG antibody and nucleic acid tests. Clinical and laboratory data were collected and analyzed. Our findings suggest that patients who develop severe illness might experience longer virus exposure times and develop a more severe inflammatory response. The IgM-IgG test is an accurate and sensitive diagnostic method. A combination of nucleic acid and IgM-IgG testing is a more sensitive and accurate approach for diagnosis and early treatment of COVID-19. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Xie, Jiajia","Ding, Chengchao","Li, Jing","Wang, Yulan","Guo, Hui","Lu, Zhaohui","Wang, Jinquan","Zheng, Changcheng","Jin, Tengchuan","Gao, Yong","He, Hongliang"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330303","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1002/jmv.25930","keywords":["covid-19","igg","igm","sars-cov-2","diagnosis"],"topics":["Diagnosis"],"weight":1,"_version_":1666138494560370688,"score":535.5009},{"pmid":32387968,"title":"Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19.","text":["Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19.","BACKGROUND: We evaluated the clinical performance of an immunochromatographic (IC) IgM/IgG antibody assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) and chest computed tomography (CT) for the diagnosis of Coronavirus disease 2019 (COVID-19). METHODS: We examined 139 serum specimens collected from 112 patients with COVID-19 and 48 serum specimens collected from 48 non-COVID-19 patients. The presence of IgM/IgG antibody for SARS-COV2 was determined using the One Step Novel Coronavirus (COVID-19) IgM/IgG Antibody Test. Chest CT was performed in COVID-19 patients on admission. FINDINGS: Of the139 COVID-19 serum specimens, IgM was detected in 27.8 %, 48.0 %, and 95.8 % of the specimens collected within 1 week, 1-2 weeks, and >2 weeks after symptom onset and IgG was detected in 3.3 %, 8.0 %, and 62.5 %, respectively. Among the 48 non-COVID-19 serum specimens, 1 generated a false-positive result for IgM. Thirty-eight of the 112 COVID-19 patients were asymptomatic, of whom 15 were positive for IgM, and 74 were symptomatic, of whom 22 were positive for IgM and 7 were positive for IgG. The diagnostic sensitivity of CT scan alone and in combination with the IC assay was 57.9 % (22/38) and 68.4 % (26/38) for the asymptomatic patients and 74.3 % (55/74) and 82.4 % (61/74) for the symptomatic patients, respectively. CONCLUSION: The IC assay had low sensitivity during the early phase of infection, and thus IC assay alone is not recommended for initial diagnostic testing for COVID-19. If RT-qPCR is not available, the combination of chest CT and IC assay may be useful for diagnosing COVID-19.","J Clin Virol","Imai, Kazuo","Tabata, Sakiko","Ikeda, Mayu","Noguchi, Sakiko","Kitagawa, Yutaro","Matuoka, Masaru","Miyoshi, Kazuyasu","Tarumoto, Norihito","Sakai, Jun","Ito, Toshimitsu","Maesaki, Shigefumi","Tamura, Kaku","Maeda, Takuya","32387968"],"abstract":["BACKGROUND: We evaluated the clinical performance of an immunochromatographic (IC) IgM/IgG antibody assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) and chest computed tomography (CT) for the diagnosis of Coronavirus disease 2019 (COVID-19). METHODS: We examined 139 serum specimens collected from 112 patients with COVID-19 and 48 serum specimens collected from 48 non-COVID-19 patients. The presence of IgM/IgG antibody for SARS-COV2 was determined using the One Step Novel Coronavirus (COVID-19) IgM/IgG Antibody Test. Chest CT was performed in COVID-19 patients on admission. FINDINGS: Of the139 COVID-19 serum specimens, IgM was detected in 27.8 %, 48.0 %, and 95.8 % of the specimens collected within 1 week, 1-2 weeks, and >2 weeks after symptom onset and IgG was detected in 3.3 %, 8.0 %, and 62.5 %, respectively. Among the 48 non-COVID-19 serum specimens, 1 generated a false-positive result for IgM. Thirty-eight of the 112 COVID-19 patients were asymptomatic, of whom 15 were positive for IgM, and 74 were symptomatic, of whom 22 were positive for IgM and 7 were positive for IgG. The diagnostic sensitivity of CT scan alone and in combination with the IC assay was 57.9 % (22/38) and 68.4 % (26/38) for the asymptomatic patients and 74.3 % (55/74) and 82.4 % (61/74) for the symptomatic patients, respectively. CONCLUSION: The IC assay had low sensitivity during the early phase of infection, and thus IC assay alone is not recommended for initial diagnostic testing for COVID-19. If RT-qPCR is not available, the combination of chest CT and IC assay may be useful for diagnosing COVID-19."],"journal":"J Clin Virol","authors":["Imai, Kazuo","Tabata, Sakiko","Ikeda, Mayu","Noguchi, Sakiko","Kitagawa, Yutaro","Matuoka, Masaru","Miyoshi, Kazuyasu","Tarumoto, Norihito","Sakai, Jun","Ito, Toshimitsu","Maesaki, Shigefumi","Tamura, Kaku","Maeda, Takuya"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32387968","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jcv.2020.104393","keywords":["covid-19","chest ct scan","immunochromatographic assay","sars-cov-2"],"topics":["Diagnosis"],"weight":1,"_version_":1666428892589588482,"score":533.8802},{"pmid":32382418,"pmcid":"PMC7202656","title":"Detection of IgM and IgG antibodies in patients with coronavirus disease 2019.","text":["Detection of IgM and IgG antibodies in patients with coronavirus disease 2019.","Objectives: This study aimed to determine the IgM and IgG responses against severe acute respiratory syndrome coronavirus (SARS-CoV)-2 in coronavirus disease 2019 (COVID-19) patients with varying illness severities. Methods: IgM and IgG antibody levels were assessed via chemiluminescence immunoassay in 338 COVID-19 patients. Results: IgM levels increased during the first week after SARS-CoV-2 infection, peaked 2 weeks and then reduced to near-background levels in most patients. IgG was detectable after 1 week and was maintained at a high level for a long period. The positive rates of IgM and/or IgG antibody detections were not significantly different among the mild, severe and critical disease groups. Severe and critical cases had higher IgM levels than mild cases, whereas the IgG level in critical cases was lower than those in both mild and severe cases. This might be because of the high disease activity and/or a compromised immune response in critical cases. The IgM antibody levels were slightly higher in deceased patients than recovered patients, but IgG levels in these groups did not significantly differ. A longitudinal detection of antibodies revealed that IgM levels decreased rapidly in recovered patients, whereas in deceased cases, either IgM levels remained high or both IgM and IgG were undetectable during the disease course. Conclusion: Quantitative detection of IgM and IgG antibodies against SARS-CoV-2 quantitatively has potential significance for evaluating the severity and prognosis of COVID-19.","Clin Transl Immunology","Hou, Hongyan","Wang, Ting","Zhang, Bo","Luo, Ying","Mao, Lie","Wang, Feng","Wu, Shiji","Sun, Ziyong","32382418"],"abstract":["Objectives: This study aimed to determine the IgM and IgG responses against severe acute respiratory syndrome coronavirus (SARS-CoV)-2 in coronavirus disease 2019 (COVID-19) patients with varying illness severities. Methods: IgM and IgG antibody levels were assessed via chemiluminescence immunoassay in 338 COVID-19 patients. Results: IgM levels increased during the first week after SARS-CoV-2 infection, peaked 2 weeks and then reduced to near-background levels in most patients. IgG was detectable after 1 week and was maintained at a high level for a long period. The positive rates of IgM and/or IgG antibody detections were not significantly different among the mild, severe and critical disease groups. Severe and critical cases had higher IgM levels than mild cases, whereas the IgG level in critical cases was lower than those in both mild and severe cases. This might be because of the high disease activity and/or a compromised immune response in critical cases. The IgM antibody levels were slightly higher in deceased patients than recovered patients, but IgG levels in these groups did not significantly differ. A longitudinal detection of antibodies revealed that IgM levels decreased rapidly in recovered patients, whereas in deceased cases, either IgM levels remained high or both IgM and IgG were undetectable during the disease course. Conclusion: Quantitative detection of IgM and IgG antibodies against SARS-CoV-2 quantitatively has potential significance for evaluating the severity and prognosis of COVID-19."],"journal":"Clin Transl Immunology","authors":["Hou, Hongyan","Wang, Ting","Zhang, Bo","Luo, Ying","Mao, Lie","Wang, Feng","Wu, Shiji","Sun, Ziyong"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32382418","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1002/cti2.1136","keywords":["covid-19","sars-cov-2","illness severity","immunoglobulin g","immunoglobulin m"],"topics":["Diagnosis"],"weight":1,"_version_":1666267276757696512,"score":527.3908},{"pmid":32473953,"title":"Diagnostic performance of 7 rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients.","text":["Diagnostic performance of 7 rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients.","OBJECTIVES: To evaluate the diagnostic performance of 7 rapid IgG/IgM tests and the Euroimmun IgA/IgG ELISA for antibodies against SARS-CoV-2 in COVID-19 patients. METHODS: Specificity was evaluated in 103 samples collected before January 2020. Sensitivity and time to seropositivity was evaluated in samples from 94 patients with COVID-19 confirmed with PCR on nasopharyngeal swab. RESULTS: Specificity [confidence interval] of lateral flow assays (LFA) was >/= 91.3% [84.0-95.5] for IgM, >/= 90.3% [82.9-94.8] for IgG, and >/= 85.4% [77.2-91.1] for the combination IgM OR IgG. Specificity of the ELISA was 96.1% [90.1-98.8] for IgG and only 73.8% [64.5-81.4] for IgA. Sensitivity 14-25 days after onset of symptoms was >/= 92.1% [78.5-98.0] to 100% [95.7-100] for IgG LFA compared to 89.5% [75.3-96.4] for IgG ELISA. Positivity of IgM OR IgG for LFA resulted in a decrease in specificity compared to IgG alone without a gain in diagnostic performance except for VivaDiag. The results for IgM varied significantly between the LFA with an average overall agreement of only 70% compared to 89% for IgG. The average dynamic trend to seropositivity for IgM was not shorter than for IgG. At time of admission to the hospital, the sensitivity of LFA was <60%. CONCLUSIONS: Sensitivity for the detection IgG antibodies 14-25 days after onset of symptoms was >/= 92.1% for all 7 LFA compared to 89.5% for the IgG ELISA. The results for IgM varied significantly and including IgM antibodies in addition to IgG for the interpretation of LFA did not improve the diagnostic performance.","Clin Microbiol Infect","Van Elslande, Jan","Houben, Els","Depypere, Melissa","Brackenier, Anouk","Desmet, Stefanie","Andre, Emmanuel","Van Ranst, Marc","Lagrou, Katrien","Vermeersch, Pieter","32473953"],"abstract":["OBJECTIVES: To evaluate the diagnostic performance of 7 rapid IgG/IgM tests and the Euroimmun IgA/IgG ELISA for antibodies against SARS-CoV-2 in COVID-19 patients. METHODS: Specificity was evaluated in 103 samples collected before January 2020. Sensitivity and time to seropositivity was evaluated in samples from 94 patients with COVID-19 confirmed with PCR on nasopharyngeal swab. RESULTS: Specificity [confidence interval] of lateral flow assays (LFA) was >/= 91.3% [84.0-95.5] for IgM, >/= 90.3% [82.9-94.8] for IgG, and >/= 85.4% [77.2-91.1] for the combination IgM OR IgG. Specificity of the ELISA was 96.1% [90.1-98.8] for IgG and only 73.8% [64.5-81.4] for IgA. Sensitivity 14-25 days after onset of symptoms was >/= 92.1% [78.5-98.0] to 100% [95.7-100] for IgG LFA compared to 89.5% [75.3-96.4] for IgG ELISA. Positivity of IgM OR IgG for LFA resulted in a decrease in specificity compared to IgG alone without a gain in diagnostic performance except for VivaDiag. The results for IgM varied significantly between the LFA with an average overall agreement of only 70% compared to 89% for IgG. The average dynamic trend to seropositivity for IgM was not shorter than for IgG. At time of admission to the hospital, the sensitivity of LFA was <60%. CONCLUSIONS: Sensitivity for the detection IgG antibodies 14-25 days after onset of symptoms was >/= 92.1% for all 7 LFA compared to 89.5% for the IgG ELISA. The results for IgM varied significantly and including IgM antibodies in addition to IgG for the interpretation of LFA did not improve the diagnostic performance."],"journal":"Clin Microbiol Infect","authors":["Van Elslande, Jan","Houben, Els","Depypere, Melissa","Brackenier, Anouk","Desmet, Stefanie","Andre, Emmanuel","Van Ranst, Marc","Lagrou, Katrien","Vermeersch, Pieter"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32473953","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.cmi.2020.05.023","keywords":["covid-19","diagnosis","elisa","immunoassay","lateral flow assay","point-of-care testing","sars-cov-2","sensitivity and specificity","seroconversion"],"topics":["Diagnosis"],"weight":1,"_version_":1668341932710952962,"score":526.45245},{"pmid":32485155,"title":"Comparison of the Elecsys(R) Anti-SARS-CoV-2 immunoassay with the EDI(TM) enzyme linked immunosorbent assays for the detection of SARS-CoV-2 antibodies in human plasma.","text":["Comparison of the Elecsys(R) Anti-SARS-CoV-2 immunoassay with the EDI(TM) enzyme linked immunosorbent assays for the detection of SARS-CoV-2 antibodies in human plasma.","BACKGROUND: Here, we report on a head-to-head comparison of the fully-automated Elecsys(R) Anti-SARS-CoV-2 immunoassay with the EDI(TM) enzyme linked immunosorbent assays (ELISA) for the detection of SARS-CoV-2 antibodies in human plasma. METHODS: SARS-CoV-2 antibodies were measured with the Elecsys(R) assay and the EDI(TM) ELISAs (IgM and IgG) in 64 SARS-CoV-2 RT-PCR confirmed COVID-19 patients with serial blood samples (n=104) collected at different time points from symptom onset. Blood samples from 200 healthy blood donors and 256 intensive care unit (ICU) patients collected before the COVID-19 outbreak were also used. RESULTS: In COVID-19 patients, the percentage of positive results rose with time from symptom onset, peaking to positivity rates after 15-22 days of 100% for the Elecsys(R) assay, of 94% for the EDI(TM) IgM-ELISA and of 100% for the EDI(TM) IgG ELISA. In the 104 blood samples, the agreement between positive/negative classifications of the Elecsys(R) assay and the EDI(TM) ELISAs (IgM or IgG) was 90%. The false positivity rates in the healthy blood donors and the ICU patients were <1% for the Elecsys(R) assay and <3% for the EDI(TM) ELISAs. CONCLUSIONS: Our results indicate a high sensitivity and specificity for the Elecsys(R) assay and an acceptable agreement with the EDI(TM) ELISAs.","Clin Chim Acta","Egger, Margot","Bundschuh, Christian","Wiesinger, Kurt","Gabriel, Christian","Clodi, Martin","Mueller, Thomas","Dieplinger, Benjamin","32485155"],"abstract":["BACKGROUND: Here, we report on a head-to-head comparison of the fully-automated Elecsys(R) Anti-SARS-CoV-2 immunoassay with the EDI(TM) enzyme linked immunosorbent assays (ELISA) for the detection of SARS-CoV-2 antibodies in human plasma. METHODS: SARS-CoV-2 antibodies were measured with the Elecsys(R) assay and the EDI(TM) ELISAs (IgM and IgG) in 64 SARS-CoV-2 RT-PCR confirmed COVID-19 patients with serial blood samples (n=104) collected at different time points from symptom onset. Blood samples from 200 healthy blood donors and 256 intensive care unit (ICU) patients collected before the COVID-19 outbreak were also used. RESULTS: In COVID-19 patients, the percentage of positive results rose with time from symptom onset, peaking to positivity rates after 15-22 days of 100% for the Elecsys(R) assay, of 94% for the EDI(TM) IgM-ELISA and of 100% for the EDI(TM) IgG ELISA. In the 104 blood samples, the agreement between positive/negative classifications of the Elecsys(R) assay and the EDI(TM) ELISAs (IgM or IgG) was 90%. The false positivity rates in the healthy blood donors and the ICU patients were <1% for the Elecsys(R) assay and <3% for the EDI(TM) ELISAs. CONCLUSIONS: Our results indicate a high sensitivity and specificity for the Elecsys(R) assay and an acceptable agreement with the EDI(TM) ELISAs."],"journal":"Clin Chim Acta","authors":["Egger, Margot","Bundschuh, Christian","Wiesinger, Kurt","Gabriel, Christian","Clodi, Martin","Mueller, Thomas","Dieplinger, Benjamin"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32485155","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.cca.2020.05.049","keywords":["covid-19","eclia","sars-cov-2","antibody testing","serological test"],"topics":["Diagnosis"],"weight":1,"_version_":1668532114723700737,"score":522.7979}]}